Document is current
Any future updates will be listed below
-
Authors
Melchers, Max https://orcid.org/0000-0001-5198-5936
Pickkers, Peter https://orcid.org/0000-0002-1104-4303
van Zanten, Arthur Raymond Hubert https://orcid.org/0000-0001-6276-7192
-
Funding
Funding for this research was provided by:
AOP Orphan Pharmaceuticals GmbH
- License Information
-
More Information
Article History
Received: 16 December 2025
Accepted: 26 January 2026
First Online: 16 February 2026
Declarations
:
: The primary study received a waiver from the Dutch ‘Medical Research Involving Human Subjects Act’ from the medical ethical committee of Wageningen University and Research on December 20, 2020. Informed consent was obtained from each subject or, when applicable, from a legal representative, next of kin, or proxy in accordance to local protocols.
: Not applicable.
: MM reported receiving honoraria for advisory board meetings, lectures, and travel expenses from AOP pharma. PP reported receiving honoraria for advisory board meetings, lectures, research, and travel expenses from AOP Pharma, AM-Pharma, EBI, 4Teen4, and Adrenomed. AvZ reported receiving honoraria for advisory board meetings, lectures, research, and travel expenses from AOP Pharma, Abbott, Baxter, Cardinal Health, Danone-Nutricia, DIM3, Dutch Medical Food, Fresenius Kabi, GE Healthcare, InBody, Mermaid, Rousselot, and Lyric.
